KOSDAQ · 308080 · Biotech & Pharma · ₩308080

ViGenCell바이젠셀

308080 · KOSDAQ · ₩308080 · 바이젠셀

₩4,870▼ ₩170 (3.37%)End-of-day · Oct 29, 2026 · End-of-day prices.

Trade

Sell Buy

Filings

Investor relations (IR) event기업설명회(IR)개최Oct 7, 2026Open on DART
Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
Quarterly report (Mar 2026)분기보고서 (2026.03)May 14, 2026Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Mar 31, 2026Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Mar 31, 2026Open on DART
Annual general meeting results정기주주총회결과Mar 26, 2026Open on DART
Audit report submitted감사보고서제출Mar 18, 2026Open on DART
Annual report (Dec 2025)사업보고서 (2025.12)Mar 18, 2026Open on DART
Notice of shareholders' meeting주주총회소집공고Mar 11, 2026Open on DART
Shareholders' meeting called주주총회소집결의Feb 25, 2026Open on DART
Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획자진취하등) (재발/불응성 급성골수성백혈병 환자를 대상으로 임상시험용의약품 (VTTri) 투여 후 안전성 및 약력학적 평가를 위한 12주, 단회 및 반복투여, 단계적 증량, 다기관, 제 1상 임상시험의 조기종료)Feb 25, 2026Open on DART
Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과) (완전관해 상태의 EBV양성 절외NK/T세포 림프종 환자를 대상으로 VTEBVN 관해 후 치료의 유효성 및 안전성을 평가하기 위한 제2상 임상시험결과보고서(CSR) 수령)Feb 24, 2026Open on DART
Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 4, 2026Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 28, 2026Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Jan 26, 2026Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 5, 2026Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Dec 31, 2025Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Dec 24, 2025Open on DART
Trading Plan Report for Executives and Major Shareholders' Specific Securities임원ㆍ주요주주특정증권등거래계획보고서Dec 24, 2025Open on DART
Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 16, 2025Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Dec 16, 2025Open on DART
Amended: 5%+ holding report[기재정정]주식등의대량보유상황보고서(일반)Dec 16, 2025Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Dec 9, 2025Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Dec 9, 2025Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Dec 9, 2025Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Dec 2, 2025Open on DART
Investor relations (IR) event기업설명회(IR)개최Nov 27, 2025Open on DART
Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과) (완전관해 상태의 EBV양성 절외NK/T세포 림프종 환자를 대상으로 VTEBVN 관해 후 치료의 유효성 및 안전성을 평가하기 위한 제2상 임상시험 Topline data 수령)Nov 25, 2025Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Nov 19, 2025Open on DART
Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 13, 2025Open on DART
Major sales or supply contract단일판매ㆍ공급계약체결Oct 1, 2025Open on DART
Major management matter relevant to investors투자판단관련주요경영사항 (iPSC(유도만능줄기세포) 유래 NK세포치료제 공동개발계약 체결)Sep 30, 2025Open on DART
Trading Plan Report for Executives and Major Shareholders' Specific Securities임원ㆍ주요주주특정증권등거래계획보고서Sep 15, 2025Open on DART
Half-year report (Jun 2025)반기보고서 (2025.06)Aug 14, 2025Open on DART
Quarterly report (Mar 2025)분기보고서 (2025.03)May 15, 2025Open on DART
Other management matters기타경영사항(자율공시) (iPSC(유도만능줄기세포) 유래 NK세포치료제 공동개발계약 체결)Apr 30, 2025Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 17, 2025Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 17, 2025Open on DART
Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 28, 2025Open on DART
Change of CEO대표이사변경Mar 27, 2025Open on DART
Annual general meeting results정기주주총회결과Mar 27, 2025Open on DART
Audit report submitted감사보고서제출Mar 19, 2025Open on DART
Annual report (Dec 2024)사업보고서 (2024.12)Mar 19, 2025Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Mar 13, 2025Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Mar 13, 2025Open on DART
Notice of shareholders' meeting주주총회소집공고Mar 12, 2025Open on DART
Exercise of Stock Purchase Options주식매수선택권행사Mar 11, 2025Open on DART
Notice of Reason for Concentrated Shareholders' Meeting Date주주총회집중일개최사유신고Feb 26, 2025Open on DART
Shareholders' meeting called주주총회소집결의Feb 26, 2025Open on DART
Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 12, 2025Open on DART

Titles in Korean until English translations are added.

Also known as: ViGenCell / 바이젠셀 / 308080 / KRX:308080

Source: KRX statistical information